StockIQ.techAbbVie Inc. (ABBV) Stock Analysis
Free AI-powered analysis and research for AbbVie Inc. stock
Sector: Healthcare
ABBV snapshot
Data as of 3 Nov 2026 close. Updated daily.
AbbVie Inc. scores 52/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 92% of its 52-week range, up 36.7% over the past year. Latest reported figures show a profit margin of 9.8% and revenue growth of +10.2%.
What is driving the score
- Strong Uptrend: +12
- MACD Bearish: -8
- High P/E (82.0): -10
- Low Liquidity (0.81 Current Ratio): -10
- Low P/B (-86.37): +5
- Strong Long-term Uptrend: +8
- Strong Momentum (+36.7% over 1 year): +8
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full ABBV report
AbbVie Inc. (ABBV) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze ABBV Now →📰 Latest Update
AbbVie Hit a New High After Earnings. There’s More Upside Left.
Tue, November 3, 2026 at 4:03 PM UTC 4 min read
AbbVie (NYSE: ABBV) reached a new high after reporting a 33% gain for the year and exceeding earnings expectations with an adjusted EPS of $3.82. The company raised its full-year EPS guidance and quarterly dividend, driven by strong performance in immunology and neuroscience, particularly from Skyrizi and Rinvoq. Analysts maintain a hold rating with a price target of $291.77, suggesting potential for further upside, especially with new pipeline developments and the recent approval of Skyrizi for Crohn's disease.